TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
2024年9月10日 - 8:00PM
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology
company committed to more effectively treating cancer using RNA
therapeutics, in collaboration with Michigan State University,
published an article in the journal Oncotarget titled,
Inhibition of miR-10b treats metastatic breast cancer by targeting
stem cell-like properties. The article was published on August 26,
2024. The study was led by Dr. Anna Moore, Professor, Director of
the Precision Health Program, and Associate Dean of the School of
Medicine at Michigan State University and scientific co-founder of
TransCode.
In this study, the authors show that stem-like
breast cancer cells increase expression of miR-10b, the molecule
targeted by TTX-MC138. The study also demonstrates that treatment
of breast cancer cells with TTX-MC138 reduces their stemness,
confirming that these properties make metastatic cells susceptible
to the therapeutic candidate’s actions.
Cancer cell stemness, or capacity for
self-renewal, is a critical component of metastasis, since
specialized cancer stem cells are those cells uniquely capable of
creating new tumors and seeding metastatic dissemination. Stemness
is a property of a distinct population of cancer cells that possess
developmental plasticity allowing them to self-renew and adapt to
new microenvironments found at the metastatic organ where they lead
to creation of metastatic tumors.
“These new findings improve our understanding of
the mechanisms behind TTX-MC138’s role in metastatic cancer,”
commented Dr. Zdravka Medarova, Chief Scientific Officer of
TransCode and an author of the publication. “This knowledge is
essential as we conduct our ongoing Phase 1 clinical trial with
this candidate because it may help better predict clinical response
in individual patients based on the unique molecular fingerprint of
their cancer. In addition, this new information may help us define
potential molecular biomarkers of therapeutic efficacy that can
serve as early surrogate indicators of clinical success. Finally,
this knowledge may help us better stratify patients for enrollment
in our later-stage clinical trials based on these predictive
biomarkers,” added Dr. Medarova.
About TransCode
Therapeutics
TransCode Therapeutics is a clinical-stage
oncology company focused on treating metastatic disease. The
company is committed to defeating cancer through the intelligent
design and effective delivery of RNA therapeutics based on its
proprietary TTX nanoparticle platform. The company’s lead
therapeutic candidate, TTX-MC138, is focused on treating metastatic
tumors which overexpress microRNA-10b, a unique, well-documented
biomarker of metastasis. In addition, TransCode is developing a
portfolio of other first-in-class RNA therapeutic candidates
designed to overcome the challenges of RNA delivery and thus unlock
therapeutic access to a variety of novel genetic targets that could
be relevant to treating a variety of cancers.
Forward-Looking Statements
This release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, including, without limitation, statements
concerning the therapeutic potential of TransCode’s TTX-MC138,
statements concerning the conduct of and results from any of the
company’s clinical trials, and statements concerning the results of
pre-clinical research. Any forward-looking statements in this press
release are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to: the
risk associated with drug discovery and development; the risk that
the results of our clinical trials will not be consistent with our
pre-clinical studies or expectations or with previous clinical
trials; risks associated with the timing and outcome of TransCode’s
planned regulatory submissions; risks associated with TransCode’s
conduct of clinical trials; risks associated with obtaining,
maintaining and protecting intellectual property; risks associated
with TransCode’s ability to enforce its patents against infringers
and defend its patent portfolio against challenges from third
parties; risks of competition from other companies developing
products for similar uses; risks associated with TransCode’s
financial condition and its need to obtain additional funding to
support its business activities, including TransCode’s ability to
continue as a going concern; risks associated with TransCode’s
dependence on third parties; and risks associated with geopolitical
events and pandemics, including the COVID-19 coronavirus. For a
discussion of these and other risks and uncertainties, and other
important factors, any of which could cause TransCode’s actual
results to differ from those contained in or implied by the
forward-looking statements, see the section entitled “Risk Factors”
in TransCode’s Annual Report on Form 10-K for the year ended
December 31, 2023, as well as discussions of potential risks,
uncertainties and other important factors in any subsequent
TransCode filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release;
TransCode undertakes no duty to update this information unless
required by law.
For more information, please
contact:
TransCode Therapeutics, Inc.Tania Montgomery-Hammon, VP of
Business Developmenttania.montgomery@transcodetherapeutics.com
TransCode Therapeutics (NASDAQ:RNAZ)
過去 株価チャート
から 9 2024 まで 10 2024
TransCode Therapeutics (NASDAQ:RNAZ)
過去 株価チャート
から 10 2023 まで 10 2024